2026/06/14 更新

お知らせ

 

写真a

イケマツ　ユウキ
池松 祐樹
IKEMATSU YUKI
所属
医学研究院 講師
職名
講師
外部リンク

研究分野

  • ライフサイエンス / 呼吸器内科学

学位

  • 九州大学大学院医学系学府医学専攻博士課程/医学博士号 （ 2020年3月 九州大学 ）

学歴

  • 九州大学     九州大学大学院医学系学府医学専攻博士課程

    2016年4月 - 2020年3月

  • 長崎大学   医学部   医学科

    - 2011年3月

論文

  • Impact of chronic obstructive pulmonary disease on clinical outcomes of EGFR-mutated non–small cell lung cancer patients receiving osimertinib 査読

    Chiyo Ishikawa, Yuki Ikematsu, Hiroaki Ogata, Toshifumi Ninomiya, Takahiro Utsumi, Norio Yamamoto, Daisuke Shibahara, Kohei Otsubo, Yoshimasa Shiraishi, Eiji Iwama, Isamu Okamoto

    International Journal of Lung Cancer   2026年6月

    　詳細を見る

    担当区分：最終著者  

  • Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer 査読

    Tanaka, K; Chamoto, K; Saeki, S; Hatae, R; Ikematsu, Y; Sakai, K; Ando, N; Sonomura, K; Kojima, S; Taketsuna, M; Kim, YH; Yoshida, H; Ozasa, H; Sakamori, Y; Hirano, T; Matsuda, F; Hirai, T; Nishio, K; Sakagami, T; Fukushima, M; Nakanishi, Y; Honjo, T; Okamoto, I

    SCIENCE TRANSLATIONAL MEDICINE   14 ( 675 )   eabq0021   2022年12月   （ ISSN:1946-6234 eISSN:1946-6242 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：Science Translational Medicine  

    Despite the success of cancer immunotherapies such as programmed cell death-1 (PD-1) and PD-1 ligand 1 (PDL1) inhibitors, patients often develop resistance. New combination therapies with PD-1/PD-L1 inhibitors are needed to overcome this issue. Bezafibrate, a ligand of peroxisome proliferator-activated receptor-γ coactivator 1α/peroxisome proliferator-activated receptor complexes, has shown a synergistic antitumor effect with PD-1 blockade in mice that is mediated by activation of mitochondria in T cells. We have therefore now performed a phase 1 trial (UMIN000017854) of bezafibrate with nivolumab in previously treated patients with advanced non-small cell lung cancer. The primary end point was the percentage of patients who experience dose-limiting toxicity, and this combination regimen was found to be well tolerated. Preplanned comprehensive analysis of plasma metabolites and gene expression in peripheral cytotoxic T cells indicated that bezafibrate promoted T cell function through up-regulation of mitochondrial metabolism including fatty acid oxidation and may thereby have prolonged the duration of response. This combination strategy targeting T cell metabolism thus has the potential to maintain antitumor activity of immune checkpoint inhibitors and warrants further validation.

    DOI： 10.1126/scitranslmed.abq0021

    Web of Science

    Scopus

    PubMed

  • Acute exacerbation in antineutrophil cytoplasmic antibody-associated interstitial lung disease: Clinical features and risk factors. 査読

    Junji Otsuka, Shigeru Yoshizawa, Yuki Ikematsu, Kunihiro Kudo, Hisayuki Osoreda, Akiko Ishimatsu, Kazuhito Taguchi, Atsushi Moriwak

    Respiratory Medicine   2022年11月

    　詳細を見る

    記述言語：英語  

  • Small-cell lung cancer from the peripheral lung is frequently accompanied by emphysema and interstitial lung disease in the background 査読

    Yuki Ikematsu, Miiru Izumi ,　Koichi Takayama, Hiroyuki Kumazoe , Kentaro Wakamatsu , Masayuki

    Thorac Cancer   2022年9月

    　詳細を見る

    担当区分：筆頭著者  

  • Coxsackievirus A11 elicits a potent oncolytic activity in human malignant pleural mesothelioma via ICAM 1 receptor 査読

    Okamura, K; Inoue, H; Ikematsu, Y; Furukawa, R; Tanaka, K; Okamoto, I

    CANCER SCIENCE   113   580 - 580   2022年2月   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　詳細を見る

  • Cytotoxic chemotherapeutic agents and osimertinib induce calreticulin exposure in non-small cell lung cancer 査読

    Furukawa, R; Inoue, H; Ikematsu, Y

    CANCER SCIENCE   113   837 - 837   2022年2月   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　詳細を見る

  • NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration 査読

    Yuki Ikematsu, Kentaro Tanaka, Toyoshi Yanagihara, Renpeng Liu, Hiroyuki Inoue, Yasuto Yoneshima, Keiichi Ota, Eiji Iwama, Shohei Takata, Kentaro Hata, Yuriko Takahata, Hiroshi Wataya, Yoichi Nakanishi, Isamu Okamoto

    LUNG CANCER   2020年8月

    　詳細を見る

    記述言語：英語  

    DOI： 10.1016/j.lungcan.2020.05.012

  • Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti–PD-1 therapy 査読

    Yuki Ikematsu, Kentaro Tanaka, Toyoshi Yanagihara, Renpeng Liu, Hiroyuki Inoue, Yasuto Yoneshima, Keiichi Ota, Eiji Iwama, Shohei Takata, Kentaro Hata, Yuriko Takahata, Hiroshi Wataya, Yoichi Nakanishi, Isamu Okamoto

    LUNG CANCER   2018年12月

    　詳細を見る

    担当区分：筆頭著者  

  • Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. 査読 国際誌

    Kentaro Tanaka, Toyoshi Yanagihara, Yuki Ikematsu, Hiroyuki Inoue, Keiichi Ota, Eiji Kashiwagi, Kunihiro Suzuki, Naoki Hamada, Ario Takeuchi, Katsunori Tatsugami, Masatoshi Eto, Kayo Ijichi, Yoshinao Oda, Kohei Otsubo, Yasuto Yoneshima, Eiji Iwama, Yoichi Nakanishi, Isamu Okamoto

    2018年7月

    　詳細を見る

  • Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1 査読

    Yuki Ikematsu, Yasuto Yoneshima, Kayo Ijichi, Kentaro Tanaka, Taishi Harada, Yoshinao Oda, Yoichi Nakanishi, Isamu Okamoto

    LUNG CANCER   2017年11月

    　詳細を見る

    担当区分：筆頭著者  

▼全件表示

書籍等出版物

  • 私の治療 査読

    池松祐樹, 藤平智道, 岡本勇（担当：分担執筆 範囲:肺癌 (非小細胞肺癌)）

    日本医事新報社  2017年7月 

  • 診断と治療のABC123　呼吸器腫瘍 査読

    池松祐樹, 岡本勇（担当：分担執筆 範囲:進行期非小細胞肺がんの薬物療法, 2ドライバー遺伝子変異陽性症例）

    最新医学社  2017年6月 

講演・口頭発表等

▼全件表示